{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:14:59Z","timestamp":1785392099613,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Cancer is the disease of the ageing. Most of the elderly cancer patients have pre-existing illnesses requiring complexity of medical care. Excessive medications would lead not only futility, but also result in adverse outcomes especially if such over-prescription is not appropriate. This study was intended to determine the prevalence of polypharmacy (PP) and potentially-inappropriate medications (PIMs) among elderly cancer patients eligible for active cancer care and their associations with hospitalization and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This was a prospective cohort study conducted among the elderly non-hematologic cancer patients (\u2265\u200965\u00a0years old) whom a medical oncologist had decided suitable for systemic cancer therapy. Demographic data including age, sex, primary site of cancer, cancer stage at diagnosis, Charlson Comorbidity Index (CCI), numbers and kinds of medications used both prior to and during cancer treatment were recorded. Hospitalizations not related to systemic cancer therapy administration and mortality were prospectively monitored. All of the patients had to be followed at least one year after cancer diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 180 eligible participants. Median age in years (IQR) was 68 (65\u201373). One hundred patients (55.56%) were male and 80 patients (44.44%) were female. Breast (35, 19.44%), lung (31, 17.22%) and colorectal (18, 10%) cancers were the most common diagnoses. Eighty-six patients (47.78%) had metastatic disease at cancer diagnosis. One hundred twenty-two patients (67.78%) had PP (5 or more medications a day) and thirty-six patients (20%) had hyper-PP (10 or more medications a day). One hundred twenty five of the whole cohort (69.4%) had PIMs. Patients with more serious CCI scores were associated with PP and hyper-PP. While patients with primary lung cancer was only the only factor associated with PIMs. When excluding opioids, laxatives and anti-emetics, the most frequently prescribed drugs during cancer treatment, the so-called corrected PP did not associate with worse 1-year survival. Factors correlated with 1-year mortality were more advanced age group (70\u00a0years old or more) (OR 2.24; 95% C.I., 1.14\u20134.41;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019), primary lung cancer (OR 2.89; 95% C.I., 1.45\u20135.78;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), metastatic disease at cancer diagnosis (OR 4.57; 95% C.I., 1.90\u201310.97;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), and unplanned hospitalizations (OR 3.09; 95% C.I.,1.60\u20135.99;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). While male gender (OR 2.35; 95% C.I., 1.17\u20134.71;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016), metastatic stage at cancer diagnosis (OR 2.74; 95% C.I., 1.33\u20135.66;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006) and corrected PP (OR 1.90; 95% C.I. 1.01\u20133.56;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.046) were the significant predictive factors of unplanned hospitalizations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among elderly cancer patients suitable for systemic cancer therapy, around two thirds of patients had PP and PIMs. Higher CCI score was the only significant predictor of PP and hyper-PP; while primary lung cancer was the sole independent factor predicting PIMs. PP was associated with unplanned hospitalizations, albeit not the survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12877-023-04471-3","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:02:21Z","timestamp":1701043341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Polypharmacy and potentially-inappropriate medications are prevalent in the elderly cancer patients receiving systemic cancer therapy and they co-relate with adverse outcomes"],"prefix":"10.1186","volume":"23","author":[{"given":"Chanyoot","family":"Bandidwattanawong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pat","family":"Rattanaserikulchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nontakorn","family":"Jetsadavanit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"issue":"4","key":"4471_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.amjopharm.2007.12.002","volume":"5","author":"ER Hajjar","year":"2007","unstructured":"Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345\u201351.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"5","key":"4471_CR2","first-page":"295","volume":"47","author":"N Azad","year":"2002","unstructured":"Azad N, Tierney M, Victor G, Kumar P. Adverse drug events in the elderly population admitted to a tertiary care hospital. J Healthc Manag. 2002;47(5):295\u2013305.","journal-title":"J Healthc Manag"},{"issue":"9","key":"4471_CR3","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1345\/aph.10351","volume":"35","author":"T J\u00f6rgensen","year":"2001","unstructured":"J\u00f6rgensen T, Johansson S, Kennerfalk A, Wallander MA, Sv\u00e4rdsudd K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother. 2001;35(9):1004\u20139.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"4471_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/cts.13438","volume":"16","author":"HJ Cho","year":"2023","unstructured":"Cho HJ, Chae J, Yoon SH, Kim DS. Factors related to polypharmacy and hyper-polypharmacy for the elderly: a nationwide cohort study using National Health Insurance data in South Korea. Clin Transl Sci. 2023;16(2):193\u2013205.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"4471_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jgo.2016.07.010","volume":"7","author":"M Sharma","year":"2016","unstructured":"Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM. Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 2016;7(5):346\u201353.","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"4471_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jgo.2011.09.001","volume":"3","author":"T J\u00f8rgensen","year":"2012","unstructured":"J\u00f8rgensen T, Herrstedt J, Friis S, Hallas J. Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006. J Geriatr Oncol. 2012;3(1):33\u201340.","journal-title":"J Geriatr Oncol"},{"issue":"13","key":"4471_CR7","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.2014.58.7550","volume":"33","author":"G Nightingale","year":"2015","unstructured":"Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33(13):1453\u20139.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"4471_CR8","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/S1040-8428(13)70214-2","volume":"64","author":"TT Yeoh","year":"2007","unstructured":"Yeoh TT, Chan LL, Poon D, Koo WH. Polypharmacy in an Asian elderly cancer patient population [Abstract]. In: Wedding U,\u00a0P\u00e9rez-Manga G, editors. 8th Meeting of the International Society of Geriatric Oncology; 2007 Nov 8\u201310; Madrid, Spain. Crit Rev Oncol Hematol. 2007;64(Suppl 1):S49.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl 1","key":"4471_CR9","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/S0261-5614(19)32731-1","volume":"38","author":"H Takemoto","year":"2019","unstructured":"Takemoto H, Mizuno S, Katsuura C, Kado A, Furukawa M, Kitani H, et al. Examination of polypharmacy and nutritional status in cancer patients [Abstract]. In: 41st ESPEN Congress; 2019 Aug 31-Sep3; Krakow, Poland. Clin Nutr. 2019;38(Suppl 1):S95.","journal-title":"Clin Nutr"},{"issue":"1","key":"4471_CR10","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1634\/theoncologist.2019-0406","volume":"25","author":"MR Mohamed","year":"2020","unstructured":"Mohamed MR, Ramsdale E, Loh KP, Arastu A, Xu H, Obrecht S, Castillo D, Sharma M, Holmes HM, Nightingale G, Juba KM, Mohile SG. Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis. Oncologist. 2020;25(1):e94\u2013108.","journal-title":"Oncologist"},{"key":"4471_CR11","doi-asserted-by":"crossref","unstructured":"Ramasubbu SK, Mahato SK, Agnihotri A, Pasricha RK, Nath UK, Das B Dr. Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: a prospective study in a tertiary care teaching hospital. Cancer Treat Res Commun. 2021;26:100277.","DOI":"10.1016\/j.ctarc.2020.100277"},{"issue":"7","key":"4471_CR12","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/cncr.34642","volume":"129","author":"MR Mohamed","year":"2023","unstructured":"Mohamed MR, Mohile SG, Juba KM, Awad H, Wells M, Loh KP, Flannery M, Culakova E, Tylock RG, Ramsdale EE. Association of polypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer. Cancer. 2023;129(7):1096\u2013104.","journal-title":"Cancer"},{"issue":"2","key":"4471_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/ggi.12241","volume":"15","author":"F Sganga","year":"2015","unstructured":"Sganga F, Landi F, Ruggiero C, Corsonello A, Vetrano DL, Lattanzio F, Cherubini A, Bernabei R, Onder G. Polypharmacy and health outcomes among older adults discharged from hospital: results from the CRIME study. Geriatr Gerontol Int. 2015;15(2):141\u20136.","journal-title":"Geriatr Gerontol Int"},{"issue":"12","key":"4471_CR14","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2165\/11319530-000000000-00000","volume":"26","author":"J Jyrkk\u00e4","year":"2009","unstructured":"Jyrkk\u00e4 J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging. 2009;26(12):1039\u201348.","journal-title":"Drugs Aging"},{"issue":"7","key":"4471_CR15","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00520-014-2171-x","volume":"22","author":"JP Turner","year":"2014","unstructured":"Turner JP, Shakib S, Singhal N, Hogan-Doran J, Prowse R, Johns S, Bell JS. Prevalence and factors associated with polypharmacy in older people with cancer. Support Care Cancer. 2014;22(7):1727\u201334.","journal-title":"Support Care Cancer"},{"issue":"1","key":"4471_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.","journal-title":"BMC Geriatr"},{"issue":"4","key":"4471_CR17","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"By the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2019","unstructured":"By the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674\u201394.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"4471_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.31557\/APJCP.2019.20.1.131","volume":"20","author":"AR Khaledi","year":"2019","unstructured":"Khaledi AR, Kazemi M, Tahmasebi M. Frequency of polypharmacy in advanced cancer patients consulted with the palliative service of Imam Khomeini Hospital (Tehran), Iran, 2017. Asian Pac J Cancer Prev. 2019;20(1):131\u20134.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"4471_CR19","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1093\/oncolo\/oyac053","volume":"27","author":"E Ramsdale","year":"2022","unstructured":"Ramsdale E, Mohamed M, Yu V, Otto E, Juba K, Awad H, Moorthi K, Plumb S, Patil A, Vogelzang N, Dib E, Mohile S. Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment. Oncologist. 2022;27(7):e580\u20138.","journal-title":"Oncologist"},{"issue":"13","key":"4471_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","volume":"7","author":"B Guthrie","year":"2015","unstructured":"Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995\u20132010. BMC Med. 2015;7(13):74.","journal-title":"BMC Med"},{"issue":"2","key":"4471_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4103\/2249-4863.117423","volume":"2","author":"V Sehgal","year":"2013","unstructured":"Sehgal V, Bajwa SJ, Sehgal R, Bajaj A, Khaira U, Kresse V. Polypharmacy and potentially inappropriate medication use as the precipitating factor in readmissions to the hospital. J Family Med Prim Care. 2013;2(2):194\u20139.","journal-title":"J Family Med Prim Care"},{"issue":"8","key":"4471_CR22","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/jgs.12942","volume":"62","author":"RJ Maggiore","year":"2014","unstructured":"Maggiore RJ, Dale W, Gross CP, Feng T, Tew WP, Mohile SG, Owusu C, Klepin HD, Lichtman SM, Gajra A, Ramani R, Katheria V, Zavala L, Hurria A, Cancer and Aging Research Group. Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc. 2014;62(8):1505\u201312.","journal-title":"J Am Geriatr Soc"},{"issue":"9836","key":"4471_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","volume":"380","author":"K Barnett","year":"2012","unstructured":"Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37\u201343.","journal-title":"Lancet"},{"issue":"6","key":"4471_CR24","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/S1470-2045(18)30348-6","volume":"19","author":"E Soto-Perez-de-Celis","year":"2018","unstructured":"Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol. 2018;19(6):e305\u201316.","journal-title":"Lancet Oncol"},{"issue":"19","key":"4471_CR25","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1200\/JCO.21.00089","volume":"39","author":"S Rostoft","year":"2021","unstructured":"Rostoft S, O\u2019Donovan A, Soubeyran P, Alibhai SMH, Hamaker ME. Geriatric assessment and management in cancer. J Clin Oncol. 2021;39(19):2058\u201367.","journal-title":"J Clin Oncol"},{"issue":"14","key":"4471_CR26","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1002\/cncr.31403","volume":"124","author":"MS Karuturi","year":"2018","unstructured":"Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, et al. Potentially inappropriate medication use in older patients with breast and colorectal cancer. Cancer. 2018;124(14):3000\u20137.","journal-title":"Cancer"},{"issue":"10314","key":"4471_CR27","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","volume":"398","author":"SG Mohile","year":"2021","unstructured":"Mohile SG, Mohamed MR, Xu H, Culakova E, Loh KP, Magnuson A, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet. 2021;398(10314):1894\u2013904.","journal-title":"Lancet"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-023-04471-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-023-04471-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-023-04471-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:02:49Z","timestamp":1701043369000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-023-04471-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4471"],"URL":"https:\/\/doi.org\/10.1186\/s12877-023-04471-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3174408\/v1","asserted-by":"object"}]},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"16 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The investigators provided the information to all of the participants regarding the necessities, benefits and any possible inconveniences during conducting this research prior to asking them for the informed consent. After signing the informed consent, demographic data regarding age, sex, primary site of cancer, cancer stage at diagnosis, and pre-existing medical conditions were collected from a participant\u2019s electronic medical records. The study was conducted according to the guidelines of the Declaration of Helsinki, and was approved by the Institutional Review Board of Faculty of Medicine Vajira Hospital (COA 022\/2565). All of the participants were informed both verbally and literally prior to sign consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"775"}}